vosilasarm + everolimus

A combination of **vosilasarm** (EP0062), an investigational selective androgen receptor modulator (SARM), and **everolimus**, an oral mammalian target of rapamycin (mTOR) inhibitor. This combination is under evaluation in clinical trials for the treatment of patients with relapsed, locally advanced or metastatic androgen receptor-positive, HER2-negative, estrogen receptor-positive (AR+/HER2-/ER+) breast cancer. Vosilasarm aims to inhibit tumor growth via AR modulation, while everolimus acts by inhibiting the mTOR pathway, thereby blocking cell growth and proliferation. Early-stage studies seek to identify optimal dosing and preliminary efficacy and safety data for this drug combination[3][5].